Internal Med Medical News about Arthritis, Rheumatoid Abatacept

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/08/09

Maxwell L et al. – There is moderate–level evidence that abatacept is efficacious and safe in the treatment of rheumatoid arthritis. Abatacept should not be used in combination with other biologics to treat rheumatoid arthritis. The withdrawal and toxicity profile appears acceptable at the present time but further long–term studies and post–marketing surveillance are required to assess harms and sustained efficacy.

Methods

The authors searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 1), MEDLINE (from 1966), EMBASE (from 1980), ACP Journal Club (from 2000), and Biosis Previews (from 1990) in March 2007 and December 2008.
The authors contacted authors of included studies and the abatacept manufacturer.
Randomized controlled trials comparing abatacept alone, or in combination with disease–modifying anti–rheumatic drugs (DMARDs) or biologics, to placebo or other DMARDs or biologics in patients with moderate to severe rheumatoid arthritis.
2 authors independently assessed search results and risk of bias, and extracted data. The authors obtained adverse event data from trials, long–term extension studies, and regulatory agencies.

Results

Seven trials with 2908 patients were included.
Compared with placebo, patients in the abatacept group were 2.2 times more likely to achieve an ACR 50 response at one year with a 21% absolute risk difference between groups.
The number needed to treat to achieve an ACR 50 response was 5.
Significant improvements in physical function and a reduction in disease activity and pain were found in abatacept–treated patients compared to placebo.
One RCT found abatacept significantly slowed the radiographic progression of joint damage at 12 months compared to placebo.
Total adverse events were greater in the abatacept group.
Other harm outcomes were not significant with the exception of a greater number of serious infections at 12 months in the abatacept group.
Serious adverse events were increased when abatacept was given in combination with other biologics